<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Treatment Selection - Comprehensive Guide</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: Aptos, 'Segoe UI', sans-serif;
            background: #f5f5f5;
            padding: 20px;
        }
        
        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            padding: 40px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
        }
        
        .header {
            text-align: center;
            margin-bottom: 50px;
        }
        
        .main-title {
            font-size: 42px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 15px;
        }
        
        .subtitle {
            font-size: 18px;
            color: #666;
        }
        
        .overview-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 20px;
            margin-bottom: 50px;
        }
        
        .overview-card {
            background: #f8f9fb;
            border-left: 5px solid #1E64C8;
            padding: 20px;
            border-radius: 8px;
            transition: all 0.3s;
        }
        
        .overview-card:hover {
            background: #e8f2ff;
            transform: translateX(5px);
        }
        
        .card-title {
            font-size: 20px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 12px;
        }
        
        .card-content {
            font-size: 16px;
            color: #333;
            line-height: 1.6;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, #1E64C8 0%, #5088d4 100%);
            color: white;
            padding: 25px;
            border-radius: 10px;
            text-align: center;
            font-size: 18px;
            font-weight: 500;
            line-height: 1.6;
            margin-bottom: 50px;
        }
        
        .section {
            margin-bottom: 60px;
            padding: 30px;
            background: #fafbfc;
            border-radius: 12px;
            border: 2px solid #e1e8ed;
        }
        
        .section-title {
            font-size: 32px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 25px;
            padding-bottom: 15px;
            border-bottom: 3px solid #1E64C8;
        }
        
        .section-description {
            font-size: 17px;
            color: #444;
            line-height: 1.8;
            margin-bottom: 30px;
        }
        
        .diagram {
            background: white;
            padding: 30px;
            border-radius: 10px;
            margin: 25px 0;
            border: 2px solid #e1e8ed;
        }
        
        .flow-container {
            display: flex;
            align-items: center;
            justify-content: space-around;
            flex-wrap: wrap;
            gap: 15px;
        }
        
        .flow-box {
            background: linear-gradient(135deg, #1E64C8 0%, #5088d4 100%);
            color: white;
            padding: 20px 25px;
            border-radius: 8px;
            font-weight: 600;
            font-size: 15px;
            text-align: center;
            min-width: 140px;
            box-shadow: 0 4px 6px rgba(30, 100, 200, 0.3);
        }
        
        .arrow {
            font-size: 28px;
            color: #1E64C8;
            font-weight: bold;
        }
        
        .details-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 20px;
            margin-top: 25px;
        }
        
        .detail-box {
            background: white;
            padding: 20px;
            border-radius: 8px;
            border-left: 4px solid #1E64C8;
        }
        
        .detail-title {
            font-size: 18px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 10px;
        }
        
        .detail-content {
            font-size: 15px;
            color: #555;
            line-height: 1.6;
        }
        
        .detail-content ul {
            margin-left: 20px;
            margin-top: 8px;
        }
        
        .detail-content li {
            margin-bottom: 6px;
        }
        
        .matrix {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 15px;
            margin: 20px 0;
        }
        
        .matrix-cell {
            background: white;
            padding: 20px;
            border-radius: 8px;
            text-align: center;
            border: 2px solid #1E64C8;
        }
        
        .matrix-label {
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 10px;
            font-size: 16px;
        }
        
        .matrix-content {
            font-size: 14px;
            color: #555;
        }
        
        .timeline {
            position: relative;
            padding-left: 40px;
            margin: 25px 0;
        }
        
        .timeline::before {
            content: '';
            position: absolute;
            left: 15px;
            top: 0;
            bottom: 0;
            width: 3px;
            background: #1E64C8;
        }
        
        .timeline-item {
            position: relative;
            background: white;
            padding: 20px;
            margin-bottom: 20px;
            border-radius: 8px;
            border: 2px solid #e1e8ed;
        }
        
        .timeline-item::before {
            content: '';
            position: absolute;
            left: -31px;
            top: 20px;
            width: 15px;
            height: 15px;
            border-radius: 50%;
            background: #1E64C8;
            border: 3px solid white;
        }
        
        .timeline-title {
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 8px;
            font-size: 16px;
        }
        
        .timeline-content {
            font-size: 15px;
            color: #555;
            line-height: 1.6;
        }
        
        .cycle-diagram {
            display: flex;
            justify-content: center;
            align-items: center;
            margin: 30px 0;
            position: relative;
            height: 300px;
        }
        
        .cycle-item {
            position: absolute;
            background: white;
            border: 3px solid #1E64C8;
            border-radius: 50%;
            width: 140px;
            height: 140px;
            display: flex;
            flex-direction: column;
            justify-content: center;
            align-items: center;
            text-align: center;
            padding: 15px;
            font-weight: 600;
            color: #1E64C8;
            font-size: 14px;
        }
        
        .cycle-item:nth-child(1) { top: 0; left: 50%; transform: translateX(-50%); }
        .cycle-item:nth-child(2) { top: 50%; right: 0; transform: translateY(-50%); }
        .cycle-item:nth-child(3) { bottom: 0; left: 50%; transform: translateX(-50%); }
        .cycle-item:nth-child(4) { top: 50%; left: 0; transform: translateY(-50%); }
        
        .key-points {
            background: #fff8e1;
            padding: 20px;
            border-radius: 8px;
            border-left: 5px solid #ffa726;
            margin-top: 20px;
        }
        
        .key-points-title {
            font-size: 18px;
            font-weight: 700;
            color: #f57c00;
            margin-bottom: 12px;
        }
        
        .key-points ul {
            margin-left: 20px;
        }
        
        .key-points li {
            margin-bottom: 8px;
            color: #555;
            line-height: 1.6;
        }
    </style>
</head>
<body>
    <div class="container">
        <!-- Header Section -->
        <div class="header">
            <div class="main-title">Treatment Selection</div>
            <div class="subtitle">Personalized Medicine Approaches for Optimal Patient Outcomes</div>
        </div>
        
        <!-- Overview Grid -->
        <div class="overview-grid">
            <div class="overview-card">
                <div class="card-title">Decision Algorithms</div>
                <div class="card-content">
                    Computational tools for treatment recommendations
                </div>
            </div>
            
            <div class="overview-card">
                <div class="card-title">Combination Therapies</div>
                <div class="card-content">
                    Biomarker-guided multi-drug regimens
                </div>
            </div>
            
            <div class="overview-card">
                <div class="card-title">Sequential Treatments</div>
                <div class="card-content">
                    Treatment sequencing based on molecular changes
                </div>
            </div>
            
            <div class="overview-card">
                <div class="card-title">Resistance Mechanisms</div>
                <div class="card-content">
                    Anticipate and overcome therapy resistance
                </div>
            </div>
        </div>
        
        <div class="highlight-box">
            Cost-effectiveness: Balance improved outcomes with healthcare resource utilization
        </div>
        
        <!-- Section 1: Decision Algorithms -->
        <div class="section">
            <div class="section-title">1. Decision Algorithms</div>
            <div class="section-description">
                Decision algorithms integrate patient-specific data including genomic profiles, clinical characteristics, and biomarker status to provide evidence-based treatment recommendations. These computational tools utilize machine learning and statistical models to optimize therapeutic selection.
            </div>
            
            <div class="diagram">
                <div class="flow-container">
                    <div class="flow-box">Patient Data<br>(Genomics, Clinical)</div>
                    <div class="arrow">→</div>
                    <div class="flow-box">Algorithm<br>Processing</div>
                    <div class="arrow">→</div>
                    <div class="flow-box">Risk<br>Stratification</div>
                    <div class="arrow">→</div>
                    <div class="flow-box">Treatment<br>Recommendation</div>
                </div>
            </div>
            
            <div class="details-grid">
                <div class="detail-box">
                    <div class="detail-title">Key Components</div>
                    <div class="detail-content">
                        <ul>
                            <li>Multi-omics data integration</li>
                            <li>Clinical decision support systems</li>
                            <li>Predictive modeling frameworks</li>
                            <li>Real-time data analysis</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Applications</div>
                    <div class="detail-content">
                        <ul>
                            <li>Cancer treatment selection</li>
                            <li>Pharmacogenomic dosing</li>
                            <li>Prognosis prediction</li>
                            <li>Treatment response forecasting</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Examples</div>
                    <div class="detail-content">
                        <ul>
                            <li>Oncotype DX for breast cancer</li>
                            <li>PREDICT tool for treatment benefit</li>
                            <li>IBM Watson for Oncology</li>
                            <li>Foundation Medicine algorithms</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Benefits</div>
                    <div class="detail-content">
                        <ul>
                            <li>Reduced treatment uncertainty</li>
                            <li>Personalized therapy selection</li>
                            <li>Improved patient outcomes</li>
                            <li>Cost-effective decision making</li>
                        </ul>
                    </div>
                </div>
            </div>
            
            <div class="key-points">
                <div class="key-points-title">Clinical Impact</div>
                <ul>
                    <li>Algorithms can reduce unnecessary chemotherapy by 30-40% in early-stage breast cancer patients</li>
                    <li>Integration of AI-based tools improves diagnostic accuracy by up to 15%</li>
                    <li>Decision support systems decrease time to treatment initiation</li>
                </ul>
            </div>
        </div>
        
        <!-- Section 2: Combination Therapies -->
        <div class="section">
            <div class="section-title">2. Combination Therapies</div>
            <div class="section-description">
                Combination therapies leverage multiple drugs targeting different molecular pathways simultaneously. Biomarker-guided approaches ensure optimal drug pairing based on tumor molecular profiles, maximizing efficacy while managing toxicity.
            </div>
            
            <div class="diagram">
                <div class="matrix">
                    <div class="matrix-cell">
                        <div class="matrix-label">Synergistic Effect</div>
                        <div class="matrix-content">Drug A + Drug B > Individual effects</div>
                    </div>
                    <div class="matrix-cell">
                        <div class="matrix-label">Multi-Pathway Targeting</div>
                        <div class="matrix-content">Simultaneous blockade of compensatory pathways</div>
                    </div>
                    <div class="matrix-cell">
                        <div class="matrix-label">Resistance Prevention</div>
                        <div class="matrix-content">Reduces emergence of resistant clones</div>
                    </div>
                    <div class="matrix-cell">
                        <div class="matrix-label">Dose Optimization</div>
                        <div class="matrix-content">Lower doses reduce toxicity</div>
                    </div>
                </div>
            </div>
            
            <div class="details-grid">
                <div class="detail-box">
                    <div class="detail-title">Strategy Types</div>
                    <div class="detail-content">
                        <ul>
                            <li>Targeted therapy combinations</li>
                            <li>Immunotherapy + chemotherapy</li>
                            <li>Dual checkpoint inhibition</li>
                            <li>Targeted + immunotherapy</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Biomarker Selection</div>
                    <div class="detail-content">
                        <ul>
                            <li>PD-L1 expression levels</li>
                            <li>Tumor mutational burden (TMB)</li>
                            <li>Microsatellite instability (MSI)</li>
                            <li>Specific gene mutations</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Clinical Examples</div>
                    <div class="detail-content">
                        <ul>
                            <li>Pembrolizumab + chemotherapy</li>
                            <li>Dabrafenib + trametinib (BRAF V600E)</li>
                            <li>Nivolumab + ipilimumab</li>
                            <li>Trastuzumab + pertuzumab (HER2+)</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Considerations</div>
                    <div class="detail-content">
                        <ul>
                            <li>Overlapping toxicity management</li>
                            <li>Drug-drug interactions</li>
                            <li>Sequential vs simultaneous dosing</li>
                            <li>Cost-benefit analysis</li>
                        </ul>
                    </div>
                </div>
            </div>
            
            <div class="key-points">
                <div class="key-points-title">Clinical Impact</div>
                <ul>
                    <li>Combination immunotherapy shows 50-60% response rates vs 30-40% monotherapy in melanoma</li>
                    <li>Dual HER2 blockade improves pathological complete response by 15-20% in breast cancer</li>
                    <li>Targeted therapy combinations can extend progression-free survival by 6-12 months</li>
                </ul>
            </div>
        </div>
        
        <!-- Section 3: Sequential Treatments -->
        <div class="section">
            <div class="section-title">3. Sequential Treatments</div>
            <div class="section-description">
                Sequential treatment strategies involve carefully planned therapy sequences based on disease evolution, molecular changes, and treatment response. This approach adapts to tumor heterogeneity and dynamic resistance patterns through continuous monitoring.
            </div>
            
            <div class="diagram">
                <div class="timeline">
                    <div class="timeline-item">
                        <div class="timeline-title">Phase 1: First-Line Therapy</div>
                        <div class="timeline-content">
                            Initial treatment based on primary molecular profile and tumor characteristics. Standard-of-care therapy with biomarker-guided selection.
                        </div>
                    </div>
                    <div class="timeline-item">
                        <div class="timeline-title">Phase 2: Monitoring & Assessment</div>
                        <div class="timeline-content">
                            Continuous evaluation through imaging, liquid biopsies, and biomarker monitoring. Detection of molecular changes and emerging resistance.
                        </div>
                    </div>
                    <div class="timeline-item">
                        <div class="timeline-title">Phase 3: Treatment Adaptation</div>
                        <div class="timeline-content">
                            Switch to second-line therapy targeting newly identified pathways or resistance mechanisms. May include combination approaches.
                        </div>
                    </div>
                    <div class="timeline-item">
                        <div class="timeline-title">Phase 4: Further Sequencing</div>
                        <div class="timeline-content">
                            Subsequent lines of therapy based on ongoing molecular profiling. Integration of novel agents and clinical trial options.
                        </div>
                    </div>
                </div>
            </div>
            
            <div class="details-grid">
                <div class="detail-box">
                    <div class="detail-title">Key Principles</div>
                    <div class="detail-content">
                        <ul>
                            <li>Dynamic disease monitoring</li>
                            <li>Molecular evolution tracking</li>
                            <li>Optimal treatment timing</li>
                            <li>Reserve effective agents</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Monitoring Tools</div>
                    <div class="detail-content">
                        <ul>
                            <li>Circulating tumor DNA (ctDNA)</li>
                            <li>Serial tissue biopsies</li>
                            <li>Radiographic assessment</li>
                            <li>Tumor marker trends</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Examples</div>
                    <div class="detail-content">
                        <ul>
                            <li>EGFR TKI → Osimertinib (T790M)</li>
                            <li>Hormone therapy → CDK4/6i → Chemotherapy</li>
                            <li>Anti-VEGF → Immunotherapy</li>
                            <li>First-gen → Second-gen targeted agents</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Advantages</div>
                    <div class="detail-content">
                        <ul>
                            <li>Addresses clonal evolution</li>
                            <li>Maximizes treatment durability</li>
                            <li>Preserves quality of life</li>
                            <li>Extends overall survival</li>
                        </ul>
                    </div>
                </div>
            </div>
            
            <div class="key-points">
                <div class="key-points-title">Clinical Impact</div>
                <ul>
                    <li>Sequential EGFR TKI therapy extends median survival to 3-4 years in EGFR+ lung cancer</li>
                    <li>Liquid biopsy-guided sequencing allows earlier detection of resistance (3-5 months advantage)</li>
                    <li>Optimal sequencing strategies can improve overall survival by 20-30% compared to random sequencing</li>
                </ul>
            </div>
        </div>
        
        <!-- Section 4: Resistance Mechanisms -->
        <div class="section">
            <div class="section-title">4. Resistance Mechanisms</div>
            <div class="section-description">
                Understanding and anticipating resistance mechanisms is crucial for therapeutic success. This involves identifying molecular pathways that enable tumor cells to evade treatment effects and developing strategies to overcome or prevent resistance.
            </div>
            
            <div class="diagram">
                <div class="cycle-diagram">
                    <div class="cycle-item">
                        <strong>Primary<br>Resistance</strong><br>
                        <small>Pre-existing mechanisms</small>
                    </div>
                    <div class="cycle-item">
                        <strong>Treatment<br>Pressure</strong><br>
                        <small>Selection advantage</small>
                    </div>
                    <div class="cycle-item">
                        <strong>Acquired<br>Resistance</strong><br>
                        <small>New mutations emerge</small>
                    </div>
                    <div class="cycle-item">
                        <strong>Adaptation<br>Strategy</strong><br>
                        <small>Treatment modification</small>
                    </div>
                </div>
            </div>
            
            <div class="details-grid">
                <div class="detail-box">
                    <div class="detail-title">Resistance Types</div>
                    <div class="detail-content">
                        <ul>
                            <li>Primary (intrinsic) resistance</li>
                            <li>Acquired resistance</li>
                            <li>Adaptive resistance</li>
                            <li>Pharmacokinetic resistance</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Molecular Mechanisms</div>
                    <div class="detail-content">
                        <ul>
                            <li>Target gene mutations (e.g., T790M)</li>
                            <li>Pathway bypass activation</li>
                            <li>Histological transformation</li>
                            <li>Immune evasion mechanisms</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Detection Methods</div>
                    <div class="detail-content">
                        <ul>
                            <li>Next-generation sequencing</li>
                            <li>Liquid biopsy analysis</li>
                            <li>Functional assays</li>
                            <li>Single-cell profiling</li>
                        </ul>
                    </div>
                </div>
                
                <div class="detail-box">
                    <div class="detail-title">Overcoming Strategies</div>
                    <div class="detail-content">
                        <ul>
                            <li>Next-generation inhibitors</li>
                            <li>Combination approaches</li>
                            <li>Intermittent dosing schedules</li>
                            <li>Immune system engagement</li>
                        </ul>
                    </div>
                </div>
            </div>
            
            <div class="key-points">
                <div class="key-points-title">Clinical Impact</div>
                <ul>
                    <li>Early resistance detection through liquid biopsy allows treatment adaptation 3-6 months earlier</li>
                    <li>Understanding resistance mechanisms enables development of next-generation drugs (e.g., osimertinib for T790M)</li>
                    <li>Combination strategies can delay resistance emergence by 50-100% compared to monotherapy</li>
                    <li>Intermittent dosing may reduce resistance development while maintaining efficacy in select cases</li>
                </ul>
            </div>
        </div>
        
        <!-- Final Summary -->
        <div class="highlight-box" style="margin-bottom: 0;">
            <strong>Integrated Approach:</strong> Optimal treatment selection combines decision algorithms, strategic combinations, adaptive sequencing, and resistance monitoring to achieve personalized, effective, and sustainable therapeutic outcomes while maintaining cost-effectiveness.
        </div>
    </div>
</body>
</html>